Hepatitis News

Browse> Home / Briefs , Daily Dose / Daily Dose & Announcements: 11/03/09 Daily Dose & Announcements: 11/03/09 >>Naturalization Event for South Asians in Montgomery County >>First Specific Viral Hepatitis & Liver Cancer Prevention Bill Introduced >>Free Hep B Vaccination and Screening >>Japanese-American Musician Emiko Featured at Japan Music Week ...

Long-term Studies Show Tenofovir Safety and Efficacy Is Sustained at 3 Years in HBeAg Positive and Negative Hepatitis B Patients SUMMARY: Long-term follow-up data from 2 clinical trials show that tenofovir remained active against hepatitis B virus and was generally well-tolerated for up to 3 years, researchers reported this past weekend at the 60th ...

It has several forms, the most common of which are A and type B. It may also produce other types, include hepatitis C, D, E and G. The disease can produce mild disease or, at times, can be fulminant, and lead to death.

Drug discovery company SCYNEXIS, Inc. presented positive data from an in vitro study evaluating the antiviral activity of SCY-635 in combination with approved and investigational non-nucleoside polymerase inhibitors, nucleoside polymerase inhibitors, protease inhibitors, ribavirin and interferon alpha 2b.

The nucleoside analogue entecavir achieves a high response rate and progressive decline in liver stiffness in patients with chronic hepatitis B, according to results from the first study in 'real-life' clinical practice reported at the Annual Meeting of the American Association for the Study of Liver Diseases .

New York, NY -- XOMA Ltd. ; Biostar Pharmaceuticals, Inc. ; Idenix Pharmaceuticals, Inc.

Main Category: Liver Disease / Hepatitis Also Included In: Clinical Trials / Drug Trials Article Date: 03 Nov 2009 A methacetin breath test that can be performed quickly and noninvasively has been proven to accurately predict survival in patients with viral hepatitis and may be used as an adjunctive tool to MELD.

BARACLUDE Demonstrated Greater Antiviral Efficacy Compared To Adefovir In New Study Of Chronic Hepatitis B Patients With Cirrhosis Bristol-Myers Squibb today announced 48-week data from an ongoing study of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir.

The hepatitis B vaccine - given to protect against infection by a virus that can cause severe liver damage and cancer - may protect for more than two decades, according to a new study.

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir , an Investigational, Once-Daily Protease Inhibitor for Hepatitis C Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases Annual Meeting BOSTON, Nov.

Presented: Tuesday, November 3, 2009, 8:00 am Eastern Time in Boston, MA ALEXANDRIA, Va.

PRINCETON, N.J. & SEATTLE - Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-nave hepatitis C virus patients.

Oct 31, 2009 - Gilead Sciences, Inc. today announced the presentation of three-year open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread among adult patients with chronic hepatitis B virus infection.

Schering-Plough Corp. said its experimental hepatitis C drug boceprevir helped eliminate the virus in about half of patients who did not respond to standard treatments.

A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer a ' and that only age is a contributing factor.

VICTORIAN health authorities have renewed their warnings over links between semi-dried tomatoes and an outbreak of hepatitis A following a further 23 cases of the infectious disease diagnosed in the past week.

Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.

Researchers in New York City are reporting their work uncovering a new epidemic of hepatitis C virus infection among men-who-have-sex-with-men who have HIV infection.

A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor.

Main Category: Melanoma / Skin Cancer Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Schering-Plough Corp.